Search clinical trials for: Parsabiv

Total 12 results

Amgen

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Spain, Belgium, Germany, Czechia, Poland, France, Greece, Hungary, Italy, United Kingdom, Lithuania, Portugal
Amgen

Recruiting

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, United States, Turkey, India, Singapore, Taiwan, Argentina, Malaysia, Russian Federation, Ukraine
Thomas Nickolas, MD MS

Completed

The Effect of Etelcalcetide on CKD-MBD (Parsabiv-MBD)

Vascular Calcification | Chronic Kidney Disease Mineral and Bone Disorder | Hyperparathyroidism; Secondary, Renal | Renal Osteodystrophy

United States
Prim. Priv. Doz. Dr. Daniel Cejka
Amgen

Completed

A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

End Stage Renal Disease

Austria
Amgen

Completed

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, Taiwan, Hong Kong, China, India, Malaysia
Amgen

Completed

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

Belgium, United States, Germany, Poland, United Kingdom, Lithuania
Amgen

Completed

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

Hyperparathyroidism, Secondary

United States
Amgen

Completed

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis

United States
KAI Pharmaceuticals
Nucleus Network Ltd

Completed

Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers

Hyperparathyroidism, Secondary

Australia
KAI Pharmaceuticals

Completed

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
KAI Pharmaceuticals

Terminated

Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism
KAI Pharmaceuticals

Completed

Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder

Secondary Hyperparathyroidism

3

Subscribe